Avenge Bio
Por um escritor misterioso
Descrição
Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors.
Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies.
The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.
Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology
Lauren Jansen - Sr. Director of Process Development - Avenge Bio
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
MartialArts Reigns (on WEBCOMICS, link in bio, C.0.D.E of Starter Perk
Michael Heffernan on LinkedIn: I am excited to announce the closing of Avenge Bio's $45 million Series A…
BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Rice lab's 'drug factory' implants cleared for human trials, Rice News, News and Media Relations
Commercialization Highlights, Office of Technology Transfer, Office of Research
Enrollment information for DRUG FACTORY Implants in Ovarian Cancer Trial is now up on the Clinical Trials website! 👏 Check here:, By Ovarcome
avengebio (@AvengeBio) / X
Avenge Bio Receives FDA Fast Track Designation for AVB-001, a Novel Cell Therapy Leveraging the LOCOcyte™ Immunotherapy Platform
Zeke Johnston - Senior Director, External Manufacturing and Supply Chain - Avenge Bio
Games Workshop - Rogue Trooper - Avenge the Quartz Zone Massacre Board Game
Commercialization Highlights, Office of Technology Transfer, Office of Research
de
por adulto (o preço varia de acordo com o tamanho do grupo)
